הכנסה לפני ניכוי ריבית, מסים ופחת: HeartBeam Inc (BEAT)

HeartBeam, Inc. (BEAT) EBITDA_Co dynamics demonstrate the current cash result of the business, where the indicator level stands at 0.00. Exclusive patents for 3D-ECG and strict FDA certifications serve as a defense for HeartBeam, Inc. (BEAT). The company generates revenue from the sale of portable sensors and cloud-based AI analysis. Demand for cardiac diagnostics is independent of seasonality or crises, ensuring maximum resilience to external shocks.

HeartBeam, Inc. is commercializing a patented rapid diagnostic system for myocardial infarctions, establishing a foundation for long-term royalty payments. This metric digitizes the net cash flow from these operations by excluding non-cash expenses, allowing investors to use absolute EBITDA trends to decouple the real fundamental stability of the medical business from short-term market fluctuations and macro-cycle volatility.